Workflow
nanOss Strata
icon
Search documents
Xtant Medical (XTNT) - 2025 Q4 - Earnings Call Transcript
2026-03-31 13:32
Xtant Medical (NYSEAM:XTNT) Q4 2025 Earnings call March 31, 2026 08:30 AM ET Company ParticipantsKevin Gardner - Managing DirectorScott Neils - CFOSean Browne - President and CEOConference Call ParticipantsChase Knickerbocker - Senior Research AnalystNone - AnalystOperatorMorning everyone, and welcome to the Xtant Medical fourth quarter and full year 2025 financial results. At this time, all participants are in a listen-only mode, and the floor will be open for questions and comments following the presentat ...
Xtant Medical (XTNT) - 2025 Q4 - Earnings Call Transcript
2026-03-31 13:32
Xtant Medical (NYSEAM:XTNT) Q4 2025 Earnings call March 31, 2026 08:30 AM ET Company ParticipantsKevin Gardner - Managing DirectorScott Neils - CFOSean Browne - President and CEOConference Call ParticipantsChase Knickerbocker - Senior Research AnalystNone - AnalystOperatorMorning everyone, and welcome to the Xtant Medical fourth quarter and full year 2025 financial results. At this time, all participants are in a listen-only mode, and the floor will be open for questions and comments following the presentat ...
Xtant Medical (XTNT) - 2025 Q4 - Earnings Call Transcript
2026-03-31 13:30
Xtant Medical (NYSEAM:XTNT) Q4 2025 Earnings call March 31, 2026 08:30 AM ET Speaker2Morning everyone, and welcome to the Xtant Medical fourth quarter and full year 2025 financial results. At this time, all participants are in a listen-only mode, and the floor will be open for questions and comments following the presentation. Please note that this conference is being recorded. I will now turn the conference over to your host, Kevin Gardner of LifeSci Advisors. Kevin, please go ahead.Speaker1Thank you, oper ...
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
Prnewswire· 2026-03-31 11:00
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results Accessibility StatementSkip Navigation Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to divestiture BELGRADE, Mont., March 31, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), ...